Briefing: Eli Lilly’s ‘triple-G’ drug leads to significant blood sugar, weight reductions in diabetes trial
Strategic angle: Diabetes patients taking an investigational drug from Eli Lilly saw significant reductions in their blood sugar and weight in a late-stage study.